raremaprare-disease reference indexOrphadata 2026-06-23 · HPO 2026-09-01
ORPHA:424002

Squamous cell carcinoma of the rectum

Synonyms: Rectal squamous cell carcinoma

Type
Disease
Group
Disorder
Inheritance
Not applicable
Age of onset
Adult
Status
active

A rare epithelial tumor of the rectum, arising from squamous cells in the rectal epithelium, without the presence of squamous-lined fistulous tracts in the rectum or a proximal extension of SCC of anal or gynecological origin. The reported symptoms are often nonspecific, such as anorexia, weight loss, lower abdominal pain, rectal bleeding and changes of bowel habits.

1

Names in Orphadata languages

12 of 12 languages
LangNameSynonyms
enSquamous cell carcinoma of the rectumRectal squamous cell carcinoma
frCarcinome épidermoïde du rectumCarcinome épidermoïde rectal
dePlattenepithelkarzinom des RektumsSquamöses Karzinom des Rektums
esCarcinoma de células escamosas de rectoCarcinoma rectal de células escamosas
itCarcinoma a cellule squamose del rettoCarcinoma rettale a cellule squamose
nlPlaveiselcelcarcinoom van rectumPlaveiselcelcarcinoom van endeldarm · Rectaal plaveiselcelcarcinoom
ptCarcinoma de células escamosas do reto
plRak płaskonabłonkowy odbytu= en
csDlaždicobuněčný karcinom rektaRektální dlaždicobuněčný karcinom
ukПлоскоклітинний рак прямої кишкиПлоскоклітинний рак прямої кишки
zh直肠鳞状细胞癌直肠鳞状细胞癌
trRektal Skuamöz Hücreli KarsinomRektal skuamöz hücreli karsinom

Definition in:

2

Cross-references

qualifier = Orphanet mapping relation
SourceCodeQualifierICD relationValidation
ICD-10C20NTBTattributedvalidated
ICD-112B92.YNTBTattributedvalidated
MONDO0018515Evalidated
UMLSC1335690Evalidated

E exact · NTBT this ORPHAcode is narrower than the target · BTNT broader than the target · ND not decided.

3

Classification

Preferential parent (Orphanet linearisation):

Parents in the classifications (1):

No children.

4

Genes

0 direct

Orphanet records no gene directly on this code.

5

Prevalence and incidence

23 records
TypeClassValueAreaQualificationValidationSource
Annual incidence1-9 / 1 000 0000.113 / 100 000EuropeValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 1 000 0000.126 / 100 000AustriaValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence<1 / 1 000 0000.052 / 100 000BelgiumValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence<1 / 1 000 0000.088 / 100 000BulgariaValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence<1 / 1 000 0000.017 / 100 000CroatiaValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 1 000 0000.26 / 100 000Czech RepublicValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 1 000 0000.157 / 100 000EstoniaValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence<1 / 1 000 0000.045 / 100 000FinlandValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence<1 / 1 000 0000.074 / 100 000FranceValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence<1 / 1 000 0000.083 / 100 000GermanyValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 1 000 0000.128 / 100 000IcelandValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence<1 / 1 000 0000.096 / 100 000IrelandValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 1 000 0000.149 / 100 000ItalyValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 1 000 0000.346 / 100 000LatviaValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 1 000 0000.116 / 100 000LithuaniaValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence<1 / 1 000 0000.071 / 100 000NorwayValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 1 000 0000.111 / 100 000PolandValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 1 000 0000.119 / 100 000PortugalValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence<1 / 1 000 0000.05 / 100 000SlovakiaValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence<1 / 1 000 0000.042 / 100 000SpainValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence<1 / 1 000 0000.084 / 100 000SwitzerlandValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence<1 / 1 000 0000.028 / 100 000NetherlandsValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]
Annual incidence1-9 / 1 000 0000.143 / 100 000United KingdomValue and classValidatedRARECARE surveillance of rare cancers in Europe[OTHER]

Value is Orphadata's ValMoy: the mean estimate per 100 000 for prevalence and incidence, the number of cases or families for case reports.

6

HPO phenotypes

Orphanet has no HPO annotation for this code in this release.

7

Sources for this card